All In Biotech

Drug Trial Radar · NCT00153062

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis

Last checked: Nov 19, 2026Latest source record: May 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 20,332 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

20,332

Actual

Start

Aug 2003

Primary completion

Apr 2008

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
GlaxoSmithKline; Bayer
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Prevention
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the trial is to determine if extended-release dipyridamole + aspirin \[Aggrenox, Asasa ntin\] is superior to clopidogrel \[Plavix\], and if telmisartan \[Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan\] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.

Conditions

  • Stroke

Interventions

  • AggrenoxDrug

    25mg aspirin, 200 mg dipyridamole

  • AggrenoxDrug

    25mg aspirin, 200 mg dipyridamole

  • Clopidogrel placeboDrug

    placebo

  • Clopidogrel placeboDrug

    placebo

  • MicardisDrug

    80 mg micardis

  • MicardisDrug

    80 mg micardis

  • Aggrenox placeboDrug

    placebo

  • Aggrenox placeboDrug

    placebo

  • ClopidogrelDrug

    75 mg clopidogrel

  • ClopidogrelDrug

    75 mg clopidogrel

  • Micardis placeboDrug

    placebo

  • Micardis placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)Time frame: time since randomization; follow-up period is 1.5 to 4.4 years
  2. Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)Time frame: time since randomization; follow-up period is 1.5 to 4.4 years

Locations

667 sites in 36 countries. Site status is shown where the registry gives one.

  • 9.159.1101 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 9.159.1173 Boehringer Ingelheim Investigational Site

    Huntsville, Alabama

  • 9.159.1058 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 9.159.1087 Boehringer Ingelheim Investigational Site

    Montgomery, Alabama

  • 9.159.1081 Boehringer Ingelheim Investigational Site

    Northport, Alabama

  • 9.159.1022 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 9.159.1133 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 9.159.1149 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 9.159.1137 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 9.159.1184 Boehringer Ingelheim Investigational Site

    Fayetteville, Arkansas

  • 9.159.1005 Boehringer Ingelheim Investigational Site

    Fort Smith, Arkansas

  • 9.159.1136 Boehringer Ingelheim Investigational Site

    Jonesboro, Arkansas

  • 9.159.1062 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 9.159.1040 Boehringer Ingelheim Investigational Site

    Berkeley, California

  • 9.159.1180 Boehringer Ingelheim Investigational Site

    Carmichael, California

  • 9.159.1114 Boehringer Ingelheim Investigational Site

    Irvine, California

  • 9.159.1202 Boehringer Ingelheim Investigational Site

    Laguna Hills, California

  • 9.159.1036 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 9.159.1052 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 9.159.1100 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 9.159.1111 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 9.159.1165 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 9.159.1134 Boehringer Ingelheim Investigational Site

    Oceanside, California

  • 9.159.1002 Boehringer Ingelheim Investigational Site

    Palo Alto, California

  • 9.159.1108 Boehringer Ingelheim Investigational Site

    Redding, California

  • 9.159.1013 Boehringer Ingelheim Investigational Site

    Sacramento, California

  • 9.159.1198 Boehringer Ingelheim Investigational Site

    Sacramento, California

  • 9.159.1029 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 9.159.1185 Boehringer Ingelheim Investigational Site

    San Francisco, California

  • 9.159.1218 Boehringer Ingelheim Investigational Site

    San Jose, California

  • 9.159.1179 Boehringer Ingelheim Investigational Site

    Santa Rosa, California

  • 9.159.1162 Boehringer Ingelheim Investigational Site

    Sylmar, California

  • 9.159.1183 Boehringer Ingelheim Investigational Site

    Torrance, California

  • 9.159.1205 Boehringer Ingelheim Investigational Site

    Walnut Creek, California

  • 9.159.1118 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 9.159.1045 Boehringer Ingelheim Investigational Site

    Englewood, Colorado

  • 9.159.1038 Boehringer Ingelheim Investigational Site

    Danbury, Connecticut

  • 9.159.1196 Boehringer Ingelheim Investigational Site

    Fairfield, Connecticut

  • 9.159.1018 Boehringer Ingelheim Investigational Site

    Hartford, Connecticut

  • 9.159.1080 Boehringer Ingelheim Investigational Site

    Newark, Delaware

Showing 40 of 667 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.